Phaseline

Companies › Servier

Servier: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 3, 1 Phase 2; Oncology; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Vorasidenib (S095032)
IDH1/IDH2 inhibitor; Isocitrate dehydrogenase [NADP], mitochondrial inhibitor; Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor
IDH1, IDH2Phase 3Residual or Recurrent Grade 2 IDH Mutant GliomaOct 2030
Ivosidenib
Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor
IDH1Phase 2Cholangiocarcinoma Non-resectableMay 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06081829IvosidenibPhase 2Cholangiocarcinoma Non-resectableOncologyMay 2027
NCT06780930Vorasidenib (S095032)Phase 3Residual or Recurrent Grade 2 IDH Mutant GliomaOncologyOct 2030

Targets

IDH1 (2) IDH2 (1)

Companies with the same targets

Eli Lilly Bristol-Myers Squibb Hutchmed Institut de Recherches Internationales Servier (I.R.I.S.) Chia Tai Tianqing Pharmaceutical Group Nuvation Bio Kissei Pharmaceutical Servier Affaires Médicales Rigel Pharmaceuticals Servier Bio-Innovation

Companies built like this

Institut de Recherches Internationales Servier (I.R.I.S.) Servier Affaires Médicales Nuvation Bio Biokin (Shanghai) Biopharmaceutical Aura Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.